Efficacy of Oral Remdesivir Compared to GS-441524 for Treatment of Cats with Naturally Occurring Effusive Feline Infectious Peritonitis: A Blinded, Non-Inferiority Study

Viruses. 2023 Aug 1;15(8):1680. doi: 10.3390/v15081680.


Nucleoside analogs GS-441524 and remdesivir (GS-5734) are effective in treating cats with feline infectious peritonitis (FIP). However, no studies have compared the efficacy between antiviral medications. The objective of this study was to evaluate the efficacy of orally administered GS-442514 (12.5-15 mg/kg) compared to orally administered remdesivir (25-30 mg/kg) in a double-blinded non-inferiority trial. Eighteen cats with effusive FIP were prospectively enrolled and randomly assigned to receive either GS-442514 or remdesivir. Cats were treated daily for 12 weeks and evaluated at week 0, 12, and 16. Survival and disease remission at week 16 were compared between groups. Five of 9 (55%) cats treated GS-441524 and 7/9 (77%) cats treated with remdesivir survived, with no difference in survival rate (p = 0.2). Remdesivir fulfilled the criteria for non-inferiority with a difference in survival of 22% (90% CI; -13.5-57.5%). Three of the 18 cats died within 48 h of enrollment. Excluding these cats, 5/6 (83%) of the cats treated with GS-441524 and 7/9 (77%) of the cats treated with remdesivir survived. These findings suggest that both orally administered GS-441524 and remdesivir are safe and effective anti-viral medications for the treatment of effusive FIP. Further optimization of the first 48 h of treatment is needed.

Keywords: FIPV; antiviral; coronavirus; feline coronavirus; nucleoside analog; therapy.

Publication types

  • Randomized Controlled Trial, Veterinary
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine
  • Animals
  • Antiviral Agents / therapeutic use
  • Cats
  • Double-Blind Method
  • Equivalence Trials as Topic
  • Feline Infectious Peritonitis* / drug therapy
  • Furans
  • Pyrroles
  • Triazines


  • Adenosine
  • Antiviral Agents
  • Furans
  • GS-441524
  • Pyrroles
  • remdesivir
  • Triazines

Grants and funding

This research was funded by the SOCK-FIP fund at the Center for Companion Animal Health at University of California, Davis, School of Veterinary Medicine grant number 2021-61-F.